TOKYO, November 5, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the company’s mid-to-long term greenhouse gas (GHG) emission reduction targets to achieve the “2 degrees Celsius target” of the Paris Agreement were approved by the Science Based Targets (SBT) Initiative1 as a science-based international initiative.
As a company dedicated to improving the health of people around the world, Astellas recognizes that addressing environmental issues including climate change is an important management issue. In order to contribute to the development of a sustainable society, Astellas is working to reduce GHG emissions and improve energy efficiency. As part of these efforts, in order to contribute to the achievement of the targets of the Paris Agreement, Astellas established new GHG emission reduction targets that cover all business activities in its Environmental Action Plan from the current fiscal year ending March 31, 2019. Accordingly, the SBT Initiative has recently approved our targets as a science-based target.
Astellas’ targets are as follows:
- Astellas commits to reduce absolute Scope2 1 and 2 GHG emissions 30% by 2030 from a 2015 base-year
- Astellas also commits to reduce Scope 3 GHG emissions 20% per JPY of revenue by 2030 from a 2015 base-year.
Astellas will continue to identify opportunities to address global environmental issues, such as climate change, in the future.